Cargando…

Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

Background: The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic after vedolizumab (VDZ) failure has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, We aim to investigate the effectiveness of anti-TNF and UST as second-line therapy in...

Descripción completa

Detalles Bibliográficos
Autores principales: Albshesh, Ahmad, Bannon, Lian, Sharar Fischler, Tali, Truyens, Marie, Vavricka, Stephan R., Tepes, Katja, Pugliese, Daniela, Savarino, Edoardo V., Zittan, Eran, Drobne, David, Roblin, Xavier, Bar-Gil Shitrit, Ariella, Armuzzi, Alessandro, Lobaton, Triana, Maharshak, Nitsan, Yanai, Henit, Ben-Horin, Shomron, Kopylov, Uri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095015/
https://www.ncbi.nlm.nih.gov/pubmed/37048587
http://dx.doi.org/10.3390/jcm12072503
_version_ 1785023979591827456
author Albshesh, Ahmad
Bannon, Lian
Sharar Fischler, Tali
Truyens, Marie
Vavricka, Stephan R.
Tepes, Katja
Pugliese, Daniela
Savarino, Edoardo V.
Zittan, Eran
Drobne, David
Roblin, Xavier
Bar-Gil Shitrit, Ariella
Armuzzi, Alessandro
Lobaton, Triana
Maharshak, Nitsan
Yanai, Henit
Ben-Horin, Shomron
Kopylov, Uri
author_facet Albshesh, Ahmad
Bannon, Lian
Sharar Fischler, Tali
Truyens, Marie
Vavricka, Stephan R.
Tepes, Katja
Pugliese, Daniela
Savarino, Edoardo V.
Zittan, Eran
Drobne, David
Roblin, Xavier
Bar-Gil Shitrit, Ariella
Armuzzi, Alessandro
Lobaton, Triana
Maharshak, Nitsan
Yanai, Henit
Ben-Horin, Shomron
Kopylov, Uri
author_sort Albshesh, Ahmad
collection PubMed
description Background: The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic after vedolizumab (VDZ) failure has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, We aim to investigate the effectiveness of anti-TNF and UST as second-line therapy in patients with Crohn’s disease (CD) who failed VDZ as a first-line treatment. The primary outcome was clinical response at week 16–22. Secondary outcomes included the rates of clinical remission, steroid-free clinical remission, CRP normalization, and adverse events. Results: Fifty-nine patients who failed on VDZ as a first-line treatment for CD were included; 52.8% patients received anti-TNF and 47.2% UST as a second-line therapy. In initial period (Week 16–22), the clinical response and remission rate was similar between both groups: 61.2% vs. 68%, p = 0.8 and 48.3% vs. 56%, p = 0.8 on anti-TNF and UST therapy, respectively. Furthermore, in the maintenance period the rate was similar: 75% vs. 82.3%, p = 0.8 and 62.5% vs. 70.5%, p = 0.8, respectively. Of the patients, 12 out of the 59 stopped the therapy, without a significant difference between the two groups (p = 0.6). Conclusion: Second-line biological therapy after VDZ failure therapy was effective in >60% of the patients with CD. No differences in effectiveness were detected between the use of anti-TNF and UST as a second line.
format Online
Article
Text
id pubmed-10095015
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100950152023-04-13 Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study Albshesh, Ahmad Bannon, Lian Sharar Fischler, Tali Truyens, Marie Vavricka, Stephan R. Tepes, Katja Pugliese, Daniela Savarino, Edoardo V. Zittan, Eran Drobne, David Roblin, Xavier Bar-Gil Shitrit, Ariella Armuzzi, Alessandro Lobaton, Triana Maharshak, Nitsan Yanai, Henit Ben-Horin, Shomron Kopylov, Uri J Clin Med Article Background: The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic after vedolizumab (VDZ) failure has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, We aim to investigate the effectiveness of anti-TNF and UST as second-line therapy in patients with Crohn’s disease (CD) who failed VDZ as a first-line treatment. The primary outcome was clinical response at week 16–22. Secondary outcomes included the rates of clinical remission, steroid-free clinical remission, CRP normalization, and adverse events. Results: Fifty-nine patients who failed on VDZ as a first-line treatment for CD were included; 52.8% patients received anti-TNF and 47.2% UST as a second-line therapy. In initial period (Week 16–22), the clinical response and remission rate was similar between both groups: 61.2% vs. 68%, p = 0.8 and 48.3% vs. 56%, p = 0.8 on anti-TNF and UST therapy, respectively. Furthermore, in the maintenance period the rate was similar: 75% vs. 82.3%, p = 0.8 and 62.5% vs. 70.5%, p = 0.8, respectively. Of the patients, 12 out of the 59 stopped the therapy, without a significant difference between the two groups (p = 0.6). Conclusion: Second-line biological therapy after VDZ failure therapy was effective in >60% of the patients with CD. No differences in effectiveness were detected between the use of anti-TNF and UST as a second line. MDPI 2023-03-26 /pmc/articles/PMC10095015/ /pubmed/37048587 http://dx.doi.org/10.3390/jcm12072503 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Albshesh, Ahmad
Bannon, Lian
Sharar Fischler, Tali
Truyens, Marie
Vavricka, Stephan R.
Tepes, Katja
Pugliese, Daniela
Savarino, Edoardo V.
Zittan, Eran
Drobne, David
Roblin, Xavier
Bar-Gil Shitrit, Ariella
Armuzzi, Alessandro
Lobaton, Triana
Maharshak, Nitsan
Yanai, Henit
Ben-Horin, Shomron
Kopylov, Uri
Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
title Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
title_full Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
title_fullStr Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
title_full_unstemmed Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
title_short Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
title_sort comparison of short- and long-term effectiveness between anti-tnf and ustekinumab after vedolizumab failure as first-line therapy in crohn’s disease: a multi-center retrospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095015/
https://www.ncbi.nlm.nih.gov/pubmed/37048587
http://dx.doi.org/10.3390/jcm12072503
work_keys_str_mv AT albsheshahmad comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT bannonlian comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT shararfischlertali comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT truyensmarie comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT vavrickastephanr comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT tepeskatja comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT pugliesedaniela comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT savarinoedoardov comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT zittaneran comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT drobnedavid comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT roblinxavier comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT bargilshitritariella comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT armuzzialessandro comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT lobatontriana comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT maharshaknitsan comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT yanaihenit comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT benhorinshomron comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy
AT kopylovuri comparisonofshortandlongtermeffectivenessbetweenantitnfandustekinumabaftervedolizumabfailureasfirstlinetherapyincrohnsdiseaseamulticenterretrospectivecohortstudy